Treatment with 45 mg vitamin K2 with 1500 mg calcium per day for postmenopausal women with osteoporosis for 48 weeks resulted in a significant increase in lumbar BMD and a significant decrease in undercarboxylated OC levels.

In healthy Caucasian postmenopausal women, raloxifene increases bone mineral density (BMD), decreases biochemical markers of bone turnover, and lowers low-density lipoprotein (LDL) cholesterol, without effects on high-density lipoprotein (HDL) cholesterol and triglycerides. This randomized, double-blind study examines the effects of raloxifene 60 mg/d (n = 483) or placebo (n = 485) in healthy postmenopausal Asian women (mean age 57 yr) from Australia, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, Taiwan, and Thailand. Serum osteocalcin, serum N-telopeptide, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were assessed at baseline and 6 months. Lumbar spine BMD was measured at baseline and 1 yr in 309 women from 4 countries. Clinical adverse events were recorded at each interim visit. At 6 months, raloxifene 60 mg/d significantly decreased osteocalcin, N-telopeptide, total cholesterol, and LDL cholesterol by medians of 15.9%, 14.6%, 5.3%, and 7.7%, respectively, from placebo. Changes in HDL cholesterol and triglycerides were similar between raloxifene and placebo. Raloxifene 60 mg/d increased mean lumbar spine BMD (1.9%) from placebo at 1 yr (P = 0.0003). The incidences of hot flashes (placebo 3.5%, raloxifene 5.6%, P = 0.12), and leg cramps (placebo 2.7%, raloxifene 4.3%, P = 0.16) were not different between groups. No case of venous thromboembolism was reported. The effects of raloxifene 60 mg/d on bone turnover, BMD, and serum lipids in healthy postmenopausal Asian women were similar to that previously reported in Caucasian women.

Objectives: To investigate and compare symptom changes and quality of life (QOL) in non equol producer postmenopausal women after consuming daidzein supplementation.Methods: This was a single randomized clinical trial. It involved menopausal women. They were divided into two groups, one received placebo that contains calcium glycerophosphate 500 mg, vitamin D3 35 IU and daidzein group contain daidzein 120 mg, contain calcium glycerophosphate 500 mg, vitamin D3 140 IU for 8 weeks. Plasma equol was measured before supplementation. Menopause QOL (MenQOL) questionnaires have been utilized in the beginning and the end of treatment to assess the QOL.Results: A total of 41 women age 45-63 years old were included in this trial, 19 (47.5%) of them receive daidzein supplementation and others received control treatment. Menopausal symptoms decreased but not statistically significant compare to control group. Conclusion:About 8 weeks daidzein supplementation was not statistically improved MenQOL status in non equol producer postmenopausal women.